Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

The vaccine can now be distributed and administered throughout the 27-country European Union.

Moderna Coronavirus Vaccine Approved in Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--European Medicines Agency (EMA) Recommends the Authorization of COVID-19 Vaccine Moderna in Europe

European Commission Authorizes COVID-19 Vaccine Moderna in Europe

If you're interested in buying this dip in Moderna, it's important to understand that you're investing in mRNA technology more than MRNA stock. The post The Opportunity May Just Be Getting Started For Moderna appeared first on InvestorPlace.

The Opportunity May Just Be Getting Started For Moderna

The move comes weeks after the regulator approved the Pfizer-BioNTech vaccine which has been marred by a slow rollout.

Moderna's Covid-19 Vaccine Approved In EU Amid Sluggish Rollout Of Vaccines Across Europe

Novavax

The re-opening narrative is dominating activity in the market and governs decisions being made in the business economy, and with good reason. Perhaps never before has so much value been tied to such a singular and distinct dynamic.

Virus Plays in Focus as 2021 Gets in Gear (NASDAQ: NVAX) (OTC US: HALB) (NASDAQ: MRNA)

The COVID-19 vaccine developed by Moderna has been approved by the European Union's medical regulator, paving the way for the vaccine to be rolled out in the 27-member bloc.

Moderna COVID-19 vaccine approved by EU medical regulator

Moderna Inc (NASDAQ: MRNA) is close to getting its fourth regulatory nod for mRNA-1273, its vaccine candidate against SARS-CoV-2. What Happened: The European Medicines Agency's Committee for Medicinal Products for Human Use, which met Wednesday, recommended that the agency grant conditional marketing authorization for mRNA-1273 in people, ages 18 years and older.

EMA Committee Recommends Conditional Approval Of Moderna's Coronavirus Vaccine

Abbott Labs

The U.S. is focusing on coronavirus testing and vaccination. And that's exactly where these companies excel.

2 Coronavirus Stocks That Will Keep Winning in 2021

The EU's vaccine regulator recommended authorization of Moderna's COVID-19 vaccine on Wednesday after experts met to review the shot. The European Medicines Agency (EMA), which assesses vaccines for use within the EU, recommended authorization of the vaccine for people aged 18 and over.

EU regulators recommended authorization of Moderna's vaccine, clearing the way for Europe to get its second COVID-19 shot

Moderna's vaccine is the second to be greenlit by European regulators.

European regulator approves Moderna Covid vaccine for use in the EU

Plus a couple of potential wild cards that could send the biotech's shares higher.

3 Big Potential Catalysts for Moderna in 2021

Shareholders were rewarded for holding through volatility.

How MRNA Stock Performed in 2020

Avantor Inc.

Becton, Dickinson and Co.

Johnson & Johnson

Pfizer

Thermo Fisher Scientific

West Pharmaceutical Services

The Covid-19 vaccine rally isn't just limited to biotech firms. Here are the top coronavirus stocks that are making mass vaccination possible.

7 Coronavirus Stocks to Buy to Make Mass Vaccination Possible

The biotech company's Covid-19 vaccine should offer protection from recent mutations. It also said it could quickly develop a new version if new mutations are resistant.

Moderna's Vaccine Should Work Against New Strains—for Now.

Is (MRNA) Outperforming Other Medical Stocks This Year?

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

Moderna (MRNA) raises lower end of its global manufacturing target for its coronavirus vaccine by 20% for 2021. The company still aims to deliver up to one billion doses in the year.

Moderna (MRNA) Raises COVID-19 Vaccine Production Target

iShares Nasdaq Biotechnology ETF

Illumina

Due to lucrative risk/reward setups and heightened fundamental demand, many active traders will be watching biotech stocks.

Active Traders Look to Biotech for 2021

Chipotle

MicroStrategy Incorporated

Tesla

These high-flying stocks are long overdue for a reality check.

5 Ultra-Popular Stocks That Could Lose 50% (or More) in 2021

BioNTech SE

The United States Food and Drug Administration has warned against changing the dosing regimen, interval, or mixing of COVID-19 vaccines in a statement issued Monday. What Happened: The health agency recognized that available data indicates the use of two specified doses of the COVID-19 vaccines — made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) — at specified intervals.

FDA Warns Against Tinkering With Pfizer, Moderna Vaccine Regimens After White House Advisor's Comments

Its new baseline case forecast for the year is 600 million doses.

Moderna Lifts Its Estimate for 2021 Coronavirus Vaccine Production by 20%

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

The COVID-19 vaccine could be the first of a long list of successes.

The Worst Mistake Moderna Investors Can Make Right Now

A government official suggested that Americans should be given one dose instead of two doses of Moderna Inc.'s COVID-19 vaccine to speed up the number of immunizations in the U.S.

Slaoui proposes a single dose of Moderna's COVID-19 vaccine to speed vaccinations

MRNA stock isn't under the radar any longer, but it is priced below where it ought to be as Covid-19 vaccines will remain in heavy demand. The post Grab Falling Moderna Shares as the Vaccine Rollout Goes Global appeared first on InvestorPlace.

Grab Falling Moderna Shares as the Vaccine Rollout Goes Global

Moderna Inc (NASDAQ: MRNA) shares were advancing Monday after the coronavirus vaccine manufacturer issued an update on its supply goals. What Happened: Cambridge, Massachusetts-based Moderna said it is raising the base-case 2021 global production estimate for its investigational coronavirus vaccine mRNA-1273 from 500 million doses to 600 million doses.

News for Moderna Stock (MRNA)